# GST levy on MRP would enhance competitive position



**Consumer Goods** 

Company Update >

September 03, 2025

CMP (Rs): 412 | TP (Rs): 475

As the GST Council is meeting to rationalize GST rates across consumption categories, we expect the government to look into cigarette taxation. We believe the government may take a call to replace cigarette compensation cess. Steady taxation in the last few years helped arrest growth in illegal volumes, with accelerated growth in legal volumes being a positive for the government. We see steady taxation as the base case scenario, where the government may hike the basic GST rate to 40% (from 28%) on value addition or MRP and shift the balance incidence to NCCD. In our view, if the imposition is on MRP, ITC's competitive position would enhance. We retain ADD on the stock with our Jun-26E TP of Rs475. We see decent stock price returns as the overhangs subside.

#### Easing in overhangs to aid ITC stock

ITC has corrected ~16% in the last one year. The correction can be attributed to: a) Concerns about an increase in cigarette taxation. b) Competitive pressure from Godfrey Phillips (GPI), which has gained ~300bps of market share from ITC. c) Inflation in prices of tobacco leaf impacting EBIT margin. d) Inflationary pressures and demand slowdown in the FMCG business. e) Steady dumping by China (via Indonesia) hurting the paper business, and f) Stake sale by BAT (a major shareholder). The first 5 overhangs would subside by H2FY26E, although another round of stake sale by BAT is expected. Tax changes for cigarettes are likely to be neutral in GST 2.0 regime.

#### Demand outlook positive for cigarettes on steady taxation

After the pandemic, cigarette smoking among youth and women increased, reflected by the industry's robust volume (legal) growth. Stable taxation is fostering a shift from illegal to legal volumes in the industry. Growth has been particularly strong in North and West India, with GPI capturing share; ITC also saw accelerated growth in these markets. Despite a broad pan-India footprint slowing relative growth, ITC is advancing with targeted brands and trade actions, reducing the risk of further market-share loss. The possibility of tax incidence on MRP (from value add) will create a setting where smaller peers have higher burdens. Margins are poised to recover as low-cost inventory is consumed, supporting expectations of low double-digit EBIT growth in cigarettes ahead.

#### Non-cigarette businesses to see recovery

Non-cigarette segments have faced pressure due to macro headwinds, although easing in inflation, the government's relaxed export policies, and anti-dumping measures for paper are setting the stage for recovery. The paper segment, which saw margin erosion from raw material price inflation and China's dumping, is likely to benefit from minimum import prices (effected) and anti-dumping duty (expected), aiding realization. Also, the margin outlook for the paper business would improve, with expected easing in raw material cost. Earnings growth in these segments would return to double digits (refer to our detailed note: Headwinds in the base; outlook to gradually improve).

ITC: Financial Snapshot (Standalone)									
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E				
Revenue	654,251	693,223	781,478	893,571	1,003,002				
EBITDA	244,629	240,236	265,823	313,548	349,480				
Adj. PAT	199,453	195,627	213,643	243,542	270,174				
Adj. EPS (Rs)	16.0	15.6	17.0	19.3	21.3				
EBITDA margin (%)	37.4	34.7	34.0	35.1	34.8				
EBITDA growth (%)	2.2	(1.8)	10.7	18.0	11.5				
Adj. EPS growth (%)	6.4	(2.1)	8.6	13.4	10.4				
RoE (%)	28.5	27.9	30.7	32.9	33.7				
RoIC (%)	55.4	55.1	58.8	63.0	65.5				
P/E (x)	25.8	14.6	24.2	21.4	19.4				
EV/EBITDA (x)	19.7	20.0	18.1	for Toom 15.4	hito Margue				
P/B (x)	7.1	This report	is intended	for ream 6.8	nite Marque 6.3				
FCFF yield (%)	2.8	4.3	2.9	4.1	4.4				

Source: Company, Emkay Research

Target Price – 12M	Jun-26
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	15.3

Stock Data	ITC IN
52-week High (Rs)	500
52-week Low (Rs)	390
Shares outstanding (mn)	12,525.4
Market-cap (Rs bn)	5,157
Market-cap (USD mn)	58,559
Net-debt, FY26E (Rs mn)	(357,558.7)
ADTV-3M (mn shares)	18
ADTV-3M (Rs mn)	5,361.8
ADTV-3M (USD mn)	60.9
Free float (%)	100.0
Nifty-50	24,715.1
INR/USD	88.1

#### Shareholding, Jun-25

Promoters (%)	0.0
FPIs/MFs (%)	38.0/46.9

Price Performance							
(%)	1M	3M	12M				
Absolute	(1.1)	(1.2)	(14.6)				
Rel. to Nifty	(1.7)	(1.9)	(12.6)				

### 1-Year share price trend (Rs)



Nitin Gupta nitin.gupta@emkayglobal.com Solutions (team.emkay@whitemarquesolution

Mohit Dodeia mohit.dodeja@emkayglobal.com +91-22-66242481

# Cigarette taxation changes likely in GST meet

Cigarette duty is a structural combination of variable payout and fixed charges per stick. Like all sin goods, cigarettes are taxed at 28% base GST, with fixed and variable cess across the length of the sticks. Currently, the imposition is up to distributor level under GST. There is central duty imposition in the form of Basic Excise and NCCD (incidence is on production).

**Exhibit 1: Current taxation on cigarettes** 

Taxation	KSFT	LSFT	RSFT	DSFT
Fixed duty incidence				
Basic Excise Duty (Rs/1,000 sticks)	5	5	5	5
NCCD (Rs/1,000 sticks)	850	630	510	510
GST fixed slab (Rs/1,000 sticks)	4,170	3,668	2,747	2,076
Variable duty incidence				
GST rate	28%	28%	28%	28%
Imposition	On value add			
GST cess	36%	5%	5%	5%
Imposition		On value	add	

Source: GOI, Emkay Research

# Two likely tax-neutral scenarios

Under GST, compensation cess is likely to end by Mar-26. We see a gradual shift in incidence to other tax heads, as GST cess ends. We see a scenario where the government would increase GST to 40% (from 28%) and the balance amount of GST incidence would shift to NCCD. In the table below, we have highlighted possible NCCD increases, which would keep the tax incidence neutral.

Exhibit 2: Expected taxation for cigarettes – Scenario 1 (GST rate shift to 40%, with levy on value addition and increase in NCCD)

KSFT	LSFT	RSFT	DSFT
5	5	5	5
5,007	2,978	2,234	1,832
40%	40%	40%	40%
	On value	add	
	5 <b>5,007</b>	5 5 5,007 2,978 40% 40%	5 5 5 <b>5,007 2,978 2,234</b>

Source: Emkay Research

Per media reports, there is a possibility of GST rate being levied on MRP; in such a case, retailers would also come in the tax net. Also, this will lead to increase in tax incidence, given a shift from value addition-based taxation to final MRP-based taxation.

Γhis report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutioι

Exhibit 3: Expected taxation for cigarettes – Scenario 2 (GST levy shifts to 40% on MRP and increase in NCCD)

Taxation	KSFT	LSFT	RSFT	DSFT
Fixed duty incidence				
Basic Excise Duty (Rs/1,000 sticks)	5	5	5	5
NCCD (Rs/1,000 sticks)	2,625	1,295	830	845
Variable duty incidence				
GST rate	40%	40%	40%	40%
Imposition		On Mi	RP	

Source: Emkay Research

Exhibit 4: Assessing taxation for RSFT segment under different scenarios (Keeping MRP at Rs10/stick)

	Current GST incidence on value addition (up to distributor)	Current tax with shift in incidence to retail	Proposed tax of 40% GST (at retail) + NCCD changes	Proposed tax of 40% GST (on MRP) + NCCD changes
Tax payout (Rs/stick)	Based on Exhibit 1	Based on Exhibit 1	Based on Exhibit 2	Based on Exhibit 3
GST	1.34	1.53	2.86	4.00
GST Cess	2.99	3.02	0.00	0.00
Basic Excise	0.01	0.01	0.01	0.01
NCCD	0.51	0.51	2.01	0.83
Total tax payout	4.84	5.06	4.87	4.84
As a % of total tax payout				
GST	28	30	59	83
GST Cess	62	60	0	0
Basic Excise	0	0	0	0
NCCD	11	10	41	17
Total	100	100	100	100
As a % of MRP				
GST	13	15	29	40
GST Cess	2	3	0	0
GST Cess	27	27	0	0
Basic Excise	0	0	0	0
NCCD	5	5	20	8
Total	48	51	49	48

Source: Emkay Research

## **Negative implications**

Any tax hike by way of tax changes will be seen negatively by the industry (legal players). In the last few years, taxation has been steady, paving the way for accelerated volume (legal) growth in the industry. We continue to see mid-single-digit taxation as accommodative, as it helps in hiking prices. Any tax hike in double digits would be negative.

# Shift in GST imposition to MRP to be positive for ITC

If there is a shift in the GST levy to MRP, we see smaller players facing margin pressures as the tax incidence on the company's realization is currently low ( $\sim$ 40% of MRP vs 100% on MRP) which implies healthy margin on offer for retail partners. Smaller peers will have to hike prices to protect margins which will have a bearing on their volumes. On steady pricing, either the smaller player will cut back on trade spending or manage with lower margins.

Γhis report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutioι

### **ITC: Standalone Financials and Valuations**

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	654,251	693,223	781,478		1,003,002
Revenue growth (%)	(0.9)	6.0	12.7	14.3	12.2
EBITDA	244,629	240,236	265,823	313,548	349,480
EBITDA growth (%)	2.2	(1.8)	10.7	18.0	11.5
Depreciation & Amortization	16,478	14,419	14,951	16,670	16,796
EBIT	228,150	225,817	250,872	296,878	332,684
EBIT growth (%)	2.4	(1.0)	11.1	18.3	12.1
Other operating income	6,591	7,715	8,634	9,667	10,634
Other income	35,383	34,543	33,628	28,285	30,449
Financial expense	457	364	400	440	484
PBT	263,076	259,996	284,100	324,723	362,649
Extraordinary items	(76)	156,317	0	0	0
Taxes	63,622	64,370	70,457	81,181	92,476
Minority interest	0	0	0	0	0
Income from JV/Associates	-	-	-	-	-
Reported PAT	199,378	351,944	213,643	243,542	270,174
PAT growth (%)	6.4	76.5	(39.3)	14.0	10.9
Adjusted PAT	199,453	195,627	213,643	243,542	270,174
Diluted EPS (Rs)	16.0	15.6	17.0	19.3	21.3
Diluted EPS growth (%)	6.4	(2.1)	8.6	13.4	10.4
DPS (Rs)	13.8	14.4	15.0	16.0	18.0
Dividend payout (%)	86.1	51.0	88.3	83.1	84.7
EBITDA margin (%)	37.4	34.7	34.0	35.1	34.8
EBIT margin (%)	34.9	32.6	32.1	33.2	33.2
Effective tax rate (%)	24.2	24.8	24.8	25.0	25.5
NOPLAT (pre-IndAS)	172,974	169,909	188,655	222,658	247,849
Shares outstanding (mn)	12,485	12,514	12,579	12,644	12,709

Source: Company, Emkay Research

Cash flows					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	227,693	225,453	250,472	296,438	332,200
Others (non-cash items)	(5,677)	(167,377)	0	0	0
Taxes paid	(56,829)	(58,446)	(70,457)	(81,181)	(92,476)
Change in NWC	7,374	(30,678)	6,265	(6,614)	(16,258)
Operating cash flow	161,182	167,510	201,631	225,754	240,746
Capital expenditure	(26,016)	41,493	(64,000)	(28,000)	(28,725)
Acquisition of business	0	0	0	0	0
Interest & dividend income	20,069	20,063	33,628	28,285	30,449
Investing cash flow	21,276	1,415	(30,372)	(29,715)	(29,001)
Equity raised/(repaid)	14,428	7,973	65	65	65
Debt raised/(repaid)	(127)	886	60	81	85
Payment of lease liabilities	0	(2,439)	0	0	0
Interest paid	(457)	(364)	(400)	(440)	(484)
Dividend paid (incl tax)	(196,061)	(174,967)	(179,577)	(188,687)	(202,306)
Others	(334)	1,253	0	0	0
Financing cash flow	(182,550)	(167,656)	(179,852)	(188,980)	(202,639)
Net chg in Cash	(93)	1,269	(8,593)	7,059	9,106
OCF	161,182	167,510	201,631	225,754	240,746
Adj. OCF (w/o NWC chg.)	153,809	198,188	195,366	232,367	257,004
FCFF	135,166	209,003	137,631	197,754	212,021
FCFE	154,778	228,703	170,860	225,599	241,986
OCF/EBITDA (%)	65.9	69.7	75.9	72.0	68.9
FCFE/PAT (%)	77.6	65.0	80.0	92.6	89.6
FCFF/NOPLAT (%)	78.1	123.0	73.0	88.8	85.5

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	12,485	12,514	12,579	12,644	12,709
Reserves & Surplus	709,848	666,487	700,553	755,409	823,277
Net worth	715,116	673,583	707,714	762,635	830,567
Minority interests	-	-	-	-	-
Non-current liab. & prov.	20,837	25,564	27,609	29,817	32,203
Total debt	681	1,568	1,627	1,709	1,794
Total liabilities & equity	746,289	706,132	742,368	799,579	869,983
Net tangible fixed assets	250,215	194,466	243,515	254,845	266,774
Net intangible assets	0	0	0	0	0
Net ROU assets	-	-	-	-	-
Capital WIP	10,870	10,707	10,707	10,707	10,707
Goodwill	-	-	-	-	-
Investments [JV/Associates]	23,936	23,936	23,936	23,936	23,936
Cash & equivalents	385,629	367,779	359,186	396,245	436,075
Current assets (ex-cash)	195,408	237,786	244,941	266,003	296,936
Current Liab. & Prov.	126,987	133,960	145,335	157,575	169,864
NWC (ex-cash)	68,422	103,826	99,606	108,428	127,072
Total assets	746,289	706,132	742,368	799,579	869,983
Net debt	(384,948)	(366,211)	(357,559)	(394,536)	(434,281)
Capital employed	746,289	706,132	742,368	799,579	869,983
Invested capital	318,637	298,292	343,121	363,273	393,846
BVPS (Rs)	57.9	54.3	56.7	60.7	65.8
Net Debt/Equity (x)	(0.5)	(0.5)	(0.5)	(0.5)	(0.5)
Net Debt/EBITDA (x)	(1.6)	(1.5)	(1.3)	(1.3)	(1.2)
Interest coverage (x)	576.3	716.3	711.5	739.3	750.6
RoCE (%)	37.7	37.1	40.8	43.8	45.2

Source: Company, Emkay Research

Valuations and key Ratios							
Y/E March	FY24	FY25	FY26E	FY27E	FY28E		
P/E (x)	25.8	14.6	24.2	21.4	19.4		
EV/CE(x)	6.7	7.1	6.7	6.3	5.7		
P/B (x)	7.1	7.6	7.3	6.8	6.3		
EV/Sales (x)	7.4	7.0	6.2	5.4	4.9		
EV/EBITDA (x)	19.7	20.0	18.1	15.4	13.8		
EV/EBIT(x)	21.1	21.3	19.2	16.2	14.5		
EV/IC (x)	15.1	16.1	14.0	13.3	12.2		
FCFF yield (%)	2.8	4.3	2.9	4.1	4.4		
FCFE yield (%)	3.0	4.4	3.3	4.4	4.7		
Dividend yield (%)	3.3	3.5	3.6	3.9	4.4		
DuPont-RoE split							
Net profit margin (%)	30.5	28.2	27.3	27.3	26.9		
Total asset turnover (x)	0.9	1.0	1.1	1.2	1.2		
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0		
RoE (%)	28.5	27.9	30.7	32.9	33.7		
DuPont-RoIC							
NOPLAT margin (%)	26.4	24.5	24.1	24.9	24.7		
IC turnover (x)	2.1	2.2	2.4	2.5	2.6		
RoIC (%)	55.4	55.1	58.8	63.0	65.5		
Operating metrics							
Core NWC days	38.2	54.7	46.5	44.3	46.2		
Total NWC days	38.2	54.7	46.5	44.3	46.2		
Fixed asset turnover	1.5	1.6	1.8	1.8	1.9		
Opex-to-revenue (%)	21.4	19.6	19.6	18.8	18.4		

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team emkay@whitemarquesolution

#### **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
17-Aug-25	411	475	Add	Nitin Gupta
01-Aug-25	416	475	Add	Nitin Gupta
30-Jun-25	416	475	Add	Nitin Gupta
24-Jun-25	414	475	Add	Nitin Gupta
09-Jun-25	423	475	Add	Nitin Gupta
23-May-25	436	475	Add	Nitin Gupta
24-Apr-25	430	450	Add	Nitin Gupta
28-Mar-25	410	450	Add	Nitin Gupta
21-Mar-25	406	490	Add	Nitin Gupta
17-Mar-25	408	490	Add	Nitin Gupta
18-Feb-25	405	490	Add	Nitin Gupta
07-Feb-25	431	490	Add	Nitin Gupta
02-Feb-25	463	520	Add	Nitin Gupta
03-Jan-25	456	520	Add	Nitin Gupta
25-Oct-24	456	520	Add	Nitin Gupta
02-Oct-24	488	520	Add	Nitin Gupta
24-Sep-24	487	520	Add	Nitin Gupta
02-Aug-24	463	520	Add	Nitin Gupta
04-Jul-24	406	470	Add	Nitin Gupta
26-Jun-24	401	460	Add	Nitin Gupta

Source: Company, Emkay Research

#### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

Γhis report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutioι

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk D

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution

#### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as spearate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of September 03, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

#### Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of September 03, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the September 03, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### **Emkay Rating Distribution**

	. 9
Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

#### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavalobal.com

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution

<sup>&</sup>lt;sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions, (team emkay@whitemarquesolution)